Skip to main content
. Author manuscript; available in PMC: 2023 Sep 29.
Published in final edited form as: Cell. 2022 Sep 29;185(20):3705–3719.e14. doi: 10.1016/j.cell.2022.09.007

Figure 3. Murine BT associated with meropenem-induced colonic GVHD.

Figure 3.

(A) Relative abundance of distinguishable Bacteroides sequence variants on day 21. (B) Longitudinal relative abundance of BT. (C) Meropenem-treated mice (Figure 1C) were stratified by median abundance of BT into a high abundant BT arm (relative abundance > 0.2) and low abundant BT arm (relative abundance < 0.2). (D) Experimental schema of murine GVHD model using decontamination therapy followed by oral introduction of BT. Mice were decontaminated as in Figure 1F followed by oral gavage of 2×107 CFUs of BT (MDA-JAX BT001) daily for 3 days. (E) Overall survival. (A - C, and E) Data are combined from three independent experiments. (F) H&E staining of histological sections of the colon collected on day 28. Bar, 100 μm. (G) GVHD histology scores of the colon collected on day 28. Data from one representative experiment are shown.